Precipio (PRPO)
Pairs hematologic-cancer pathology testing with proprietary diagnostic products.
Something off on this page? Send us feedback.
Offers specialized cancer diagnostic testing through its pathology laboratory and sells HemeScreen and IV-Cell diagnostic products. The lab and product divisions work together, with laboratory services functioning as a self-funded R&D unit.
Combines a clinical hematologic-cancer pathology laboratory with proprietary diagnostic-product development. The pathology-services division supplies specialized cancer diagnostic testing to physicians, hospitals, and laboratories, principally for hematologic cancers.
Its product division markets HemeScreen and IV-Cell. HemeScreen has expanded from a myeloproliferative-neoplasms panel into panels for acute myeloid leukemia, chronic lymphocytic leukemia, cytopenia, and BCR-ABL; the company also released BCR-ABL1 and Bloodhound MPN assays with complementary analysis software.
Laboratory services are integrated with product development and function as a self-funded R&D unit. The pathology-services business depends on testing volumes and reimbursement levels.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.1M · Total debt $3.3M · Total assets $21.3M · Shareholders' equity $14.8M
- Revenue
- $7.0M
- Operating income
- −$599.0K
- Net income
- −$219.0K
No dividends on record.
| Institutions | 8.83% | 158.1K shares | |
|---|---|---|---|
| 17 holders · as of Jun 30, 2026 | |||
| Insiders | 11.00% | 197.0K shares | |
| 8 holders · as of Jul 16, 2026 | |||
| Other | 80.17% | 1.44M shares | |
| remainder | |||
1.79M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Leviticus Partners LPInstitution | 8.86% | 158,635 | filed Feb 10, 2026 |
David A. EklundInsider | 4.71% | 84,250 | filed Aug 2, 2024 |
David Seth CohenInsiderdirector | 3.08% | 55,199 | filed Jul 16, 2026 |
Vanguard Capital Management LLCInstitution | 2.58% | 46,148 | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 1.94% | 34,655 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 21, 2026 | Richard A. Sandberg | director | −900 | $25.02 |
| May 20, 2026 | Richard A. Sandberg | director | −2,534 | $24.91 |
| May 19, 2026 | Richard A. Sandberg | director | −600 | $24.42 |
| Apr 1, 2026 | Ahmed Zaki Sabet | officer: Chief Operating Officer | +19 | $27.93 |
| Jul 8, 2025 | Ahmed Zaki Sabet | officer: Chief Operating Officer | +31 | $16.30 |
- NeoGenomics
Cancer-focused oncology diagnostics and pathology laboratory network
- Labcorp
National laboratory services provider with oncology diagnostics
- Quest Diagnostics
National diagnostic-services provider with oncology and molecular testing
- Fulgent Genetics
Specialty pathology and hematopathology testing through Inform Diagnostics
- Guardant Health
Liquid-biopsy oncology testing for therapy selection and monitoring
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Precipio | $26.27 | −0.47% | $47.8M | — | — | 1.7 | +24.2% |
| NeoGenomics | $19.28 | +2.12% | $498.7M | — | 67.9 | 0.7 | +11.2% |
| Labcorp | $311.54 | +0.05% | $26.32B | 26.6 | 16.4 | 1.8 | +5.8% |
| Quest Diagnostics | $234.76 | −0.04% | $27.03B | 26.0 | 20.5 | 2.3 | +10.2% |
| Fulgent Genetics | $21.65 | +0.05% | $611.7M | — | — | 1.9 | +4.4% |
| Guardant Health | $177.17 | +0.03% | $23.33B | — | — | 19.7 | +44.3% |
| Median | 26.3 | 20.5 | 1.9 | +10.2% |